30th Oct 2014 07:23
LONDON (Alliance News) - AstraZeneca PLC Thursday said the US Food and Drug Administration has approved its once-daily XIGDUO XR drug for the treatment of adults with type 2 diabetes.
XIGDUO XR is already approved in Australia for the treatment of adults with type 2 diabetes, along with diet and exercise. XIGDUO, meanwhile, is approved in the European Union.
XIGDUO XR combines two anti-hyperglycaemic agents with complementary mechanisms of action: dapagliflozin, an inhibitor of sodium-glucose cotransporter, and metformin hydrochloride extended-release, a biguanide, in a once-daily oral tablet. Sodium-glucose cotransporter 2 inhibitors are a relatively new class of medicines that remove glucose from the body via the kidneys.
By Steve McGrath; [email protected]; @stevemcgrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca